Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes

    ... (MDS) is associated with the hypomethylating agent decitabine . A retrospective pooled analysis of 2 decitabine clinical trials in patients with MDS conducted Cox regression ...

    Research Article last updated 06/02/2014 - 11:03am.

  2. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

    ... the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We ... transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this ...

    Research Article last updated 03/05/2013 - 9:07am.

  3. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

    ... Clinical experience with 5-azacytidine and decitabine treatment of myelodysplastic syndromes (MDS), ... mainstays such as cytarabine. For example, 5-azacytidine and decitabine produce remissions and better overall survival in MDS with high-risk ...

    Research Article last updated 01/08/2014 - 9:30am.

  4. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... DNMT3A mutations are associated with a good response to decitabine therapy. In addition, patients with del5q subtype harboring TP53 ...

    Research Article last updated 02/01/2017 - 8:15am.

  5. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... cytotoxic chemotherapies, hypomethylating agents such as decitabine (5-aza-2'-deoxycytidine) and azacitidine ... a safe and feasible alternative also for frail patients. Decitabine has been shown to be active in numerous studies including ... and in MDS with poor-risk cytogenetics . Furthermore, decitabine has been studied in the allograft setting and in combination ...

    Research Article last updated 11/05/2012 - 9:34am.

  6. Decitabine treatment of patients with higher-risk myelodysplastic syndromes.

    ... of patients with myelodysplastic syndromes , decitabine has also gained marketing approval in several other countries. Rates of complete remission (CR) reported for decitabine range from 9% in the US registration trial to 34% in a study of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

    ... studies focusing on hypomethylating agents, such as decitabine (5-aza-deoxycytidine) and 5- azacitidine , have led to the ... available on the clinical efficacy and safety profile for decitabine as a treatment for MDS. Although not fully understood, decitabine's ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Decitabine in the treatment of myelodysplastic syndromes.

    ... to cellular differentiation and/or apoptosis . Decitabine is a cytidine analogue that has activity as a hypomethylating ... studies have confirmed the clinical activity of low-dose decitabine in patients with high-risk MDS, leading to responses in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

    ... PURPOSE: Decitabine , a DNA-targeted hypomethylating agent, is approved by the ... PATIENTS AND METHODS: Patients were treated with decitabine 20 mg/m(2) by IV infusion daily for 5 consecutive days every 4 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine

    ...

    Research Article last updated 11/28/2016 - 9:50am.